Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/0008-5472.can-19-3176
Abstract: These findings suggest that targeting the IL1β inflammatory pathway might be critical in reducing tumor-promoting inflammation and lung cancer incidence. In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), inhibition of the IL1β inflammatory pathway by… read more here.
Keywords: canakinumab; lung cancer; cancer; cantos ... See more keywords